1S70 Stock Chart & Stats
€8.05
€0.15(2.33%)
At close: 4:00 PM EDT
€8.05
€0.15(2.33%)
Day’s Range― - ―
52-Week Range€4.68 - €9.60
Previous CloseN/A
Volume11.00
Average Volume (3M)37.00
Market Cap
€171.04M
Enterprise Value€227.40M
Total Cash (Recent Filing)€147.61M
Total Debt (Recent Filing)€63.85M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Nov 05, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding30,255,352
10 Day Avg. Volume26
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.09Price Target Upside261.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.64
Revenue Forecast (FY)€372.79K
Bulls Say, Bears Say
Bulls Say
Clinical DurabilitySustained symptom improvement after retreatment supports the possibility of durable clinical benefit and a repeat-treatment pathway for Descartes-08. The absence of new safety concerns also strengthens the program’s profile as it advances toward Phase 3 testing and potential regulatory submission.
Differentiated Therapy DesignTransient mRNA engineering may offer a differentiated cell-therapy approach by avoiding permanent genetic modification while targeting therapeutic receptor expression. This design could support a distinct safety and treatment profile if clinical development continues to validate the platform across autoimmune diseases.
Modest Absolute DebtLow absolute debt reduces direct interest and refinancing pressure compared with a heavily leveraged development-stage company. Although negative equity remains a major weakness, modest debt may preserve some flexibility for research investment and financing decisions during ongoing clinical development.
Bears Say
Revenue ContractionThe sharp revenue contraction demonstrates that Cartesian does not yet have a stable commercial earnings base. With TTM revenue only $1.5M and materially below earlier periods, the company remains dependent on successful clinical execution and future financing or partnerships rather than recurring product sales.
Persistent Cash BurnSustained operating and free-cash-flow deficits create an ongoing funding requirement typical of clinical-stage biotech but still material for shareholders. Burn remained similar to 2025 and worse than 2024, limiting internal reinvestment capacity and increasing reliance on external capital.
Negative Equity And LossesDeep losses and negative equity indicate that accumulated deficits have materially weakened the capital structure. This reduces balance-sheet resilience, raises dependence on future financing, and leaves less capacity to absorb clinical setbacks or sustain development spending without dilution or other capital support.
Cartesian Therapeutics News
1S70 FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was €4.68 and its highest was €9.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is €171.04M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 20 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Aug 06, 2026. The company reported €0.406 earnings per share for the quarter, beating the consensus estimate of -€0.775 by €1.18.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 30,255,352 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of €0.406 in its last earnings report, beating expectations of -€0.775. Following the earnings report the stock price went up 2.878%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in DE:1S70
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€29.09 (261.36% Upside)
€29.09 (261.36% Upside)
Blogger Sentiment
Bullish
DE:1S70 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.81%
12-Months-Change
Fundamentals
Return on Equity
141.41%
Trailing 12-Months
Asset Growth
-18.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
1S70 Stock 12 Month Forecast
Average Price Target
€29.09
▲(261.36% Upside)